UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION

                             Washington, D.C. 20549

                                    FORM 10-Q

              [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)
                     OF THE SECURITIES EXCHANGE ACT OF 1934

                For the Quarterly Period Ended December 31, 2001

                                       OR

              [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)
                     OF THE SECURITIES EXCHANGE ACT OF 1934

                   For the transition period from ____ to____

                          Commission File No. 000-18799


                       HEALTH MANAGEMENT ASSOCIATES, INC.
     -----------------------------------------------------------------------
             (Exact name of Registrant as specified in its charter)

          Delaware                                         61-0963645
--------------------------------                 -------------------------------
  (State or other jurisdiction                          (I.R.S. Employer
of incorporation or organization)                     Identification No.)

   5811 Pelican Bay Boulevard, Suite 500, Naples, Florida         34108-2710
---------------------------------------------------------       ----------------
       (Address of principal executive offices)                   (Zip Code)

                                  (941)598-3131
               --------------------------------------------------
              (Registrant's telephone number, including area code)

Indicate by check mark whether the Registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months, and (2) has been subject to such filing requirements
for the past 90 days.

                                                             Yes  X   No
                                                                 ---     ---

At February 6, 2002, the following shares of the Registrant were outstanding:

                  Class A Common Stock   241,734,411 shares



                       HEALTH MANAGEMENT ASSOCIATES, INC.
                                    FORM 10-Q

                FOR THE QUARTERLY PERIOD ENDED DECEMBER 31, 2001



                                      INDEX
                                      -----


PART I.      FINANCIAL INFORMATION                                          Page

Item 1.      Financial Statements
                                                                         
         Consolidated Statements of Income--
           Three Months Ended December 31, 2001 and 2000 ..................    3

         Condensed Consolidated Balance Sheets--
           December 31, 2001 and September 30, 2001 .......................    4

         Condensed Consolidated Statements of Cash Flows--
           Three Months Ended December 31, 2001 and 2000 ..................    5

         Notes to Interim Condensed Consolidated Financial Statements .....    6-8

Item 2.      Management's Discussion and Analysis of Financial
                Condition and Results of Operations .......................    9-12

Item 3.      Quantitative and Qualitative Disclosures
                About Market Risk..........................................    12


PART II.     OTHER INFORMATION ............................................    13

Signatures ................................................................    14

Index To Exhibits .........................................................    15-16


                                       2



PART I.  FINANCIAL INFORMATION
Item 1.  Financial Statements

                       HEALTH MANAGEMENT ASSOCIATES, INC.

                        CONSOLIDATED STATEMENTS OF INCOME
                    (in thousands, except per share amounts)
                                   (unaudited)


                                                            Three months ended
                                                                December 31,
                                                           ---------------------
                                                             2001         2000
                                                           --------     --------
                                                                  
Net patient service revenue ..........................     $495,821     $434,237

Costs and expenses:
   Salaries and benefits .............................      195,748      169,153
   Supplies and other ................................      143,433      126,069
   Provision for doubtful accounts ...................       36,878       35,905
   Depreciation and amortization .....................       21,648       21,430
   Rent expense ......................................       10,926        9,522
   Interest, net .....................................        4,116        6,036
                                                           --------     --------
       Total costs and expenses ......................      412,749      368,115
                                                           --------     --------


Income before income taxes ...........................       83,072       66,122

Provision for income taxes ...........................       32,606       25,944
                                                           --------     --------


Net income ...........................................     $ 50,466     $ 40,178
                                                           ========     ========


Net income per share:
   Basic .............................................     $    .21     $    .17
                                                           ========     ========
   Diluted ...........................................     $    .20     $    .16
                                                           ========     ========


Weighted average number of shares outstanding:

   Basic .............................................      243,649      243,234
                                                           ========     ========
   Diluted ...........................................      263,365      264,297
                                                           ========     ========



                             See accompanying notes.

                                       3



                       HEALTH MANAGEMENT ASSOCIATES, INC.

                      CONDENSED CONSOLIDATED BALANCE SHEETS
                                 (in thousands)



                                     ASSETS
                                     -------

                                                                   December 31,             September 30,
                                                                       2001                      2001
                                                                   ------------             -------------
                                                                   (Unaudited)
                                                                                      
Current assets:
  Cash and cash equivalents ....................................   $   118,160              $    70,263
  Receivables--net .............................................       381,713                  380,136
  Supplies, prepaids and other assets ..........................        79,876                   69,139
  Funds held by trustee ........................................         2,973                    1,892
  Deferred income taxes ........................................        43,801                   43,801
                                                                   -----------              -----------
       Total current assets ....................................       626,523                  565,231

Property, plant and equipment ..................................     1,569,389                1,453,903
  Less accumulated depreciation and amortization ...............      (384,244)                (364,490)
                                                                   -----------              -----------
       Net property, plant and equipment .......................     1,185,145                1,089,413

Other assets:
  Funds held by trustee ........................................         1,744                    1,791
  Excess of cost over acquired net assets, net .................       302,281                  251,315
  Deferred charges and other assets ............................        34,970                   33,827
                                                                   -----------              -----------
       Total ...................................................       338,995                  286,933
                                                                   -----------              -----------

                                                                   $ 2,150,663              $ 1,941,577
                                                                   ===========              ===========

                      LIABILITIES AND STOCKHOLDERS' EQUITY
                      ------------------------------------

Current liabilities:
  Accounts payable .............................................   $   122,810              $    91,862
  Accrued expenses and other liabilities .......................        98,764                   88,117
  Income taxes--currently payable and deferred .................        29,726                    1,356
  Current maturities of long-term debt .........................         7,322                    6,752
                                                                   -----------              -----------
       Total current liabilities ...............................       258,622                  188,087

Deferred income taxes ..........................................        34,286                   34,286
Other long-term liabilities ....................................        36,894                   36,565
Long-term debt .................................................       600,038                  428,990

Stockholders' equity:
  Preferred stock, $.01 par value, 5,000
    shares authorized ..........................................             -                        -
  Common stock, Class A, $.01 par value, 750,000
    shares authorized, 259,115 and 258,074
    shares issued at December 31, 2001 and
    September 30, 2001, respectively ...........................         2,591                    2,581
  Additional paid-in capital ...................................       343,193                  340,192
  Retained earnings ............................................     1,075,613                1,025,147
                                                                   -----------              -----------
                                                                     1,421,397                1,367,920
  Less treasury stock, 17,096 and 12,639 shares
    at cost at December 31, 2001 and
    September 30, 2001, respectively ...........................      (200,574)                (114,271)
                                                                   -----------              -----------
       Total stockholders' equity ..............................     1,220,823                1,253,649
                                                                   -----------              -----------

                                                                   $ 2,150,663              $ 1,941,577
                                                                   ===========              ===========


                             See accompanying notes.

                                        4



                       HEALTH MANAGEMENT ASSOCIATES, INC.

                 CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
                                 (in thousands)
                                   (unaudited)



                                                                                            Three months ended
                                                                                               December 31,
                                                                                    ---------------------------------
                                                                                       2001                   2000
                                                                                    ---------               ---------
                                                                                                      
Cash flows from operating activities:
  Net income ...........................................................            $  50,466               $  40,178
  Adjustments to reconcile net income to net cash provided by operating
    activities:
     Depreciation and amortization .....................................               21,648                  21,430
     Provision for doubtful accounts ...................................               36,878                  35,905
     Loss on sale of fixed assets ......................................                    -                       4

     Changes in assets and liabilities:
       Receivables .....................................................              (23,690)                (61,839)
       Supplies and other current assets ...............................               (7,147)                 (5,746)
       Deferred charges and other assets ...............................                  898                  (9,980)
       Accounts payable ................................................               21,974                   7,989
       Accrued expenses and other liabilities ..........................                1,216                   5,376
       Income taxes--
         currently payable and deferred ................................               28,370                  21,892
       Other long term liabilities .....................................               (2,171)                   (178)
                                                                                    ---------               ---------

          Net cash provided by operating activities ....................              128,442                  55,031
                                                                                    ---------               ---------

Cash flows from investing activities:
  Acquisition of facilities, net of cash acquired ......................             (186,520)                      -
  Additions to property, plant and equipment ...........................              (20,582)                (16,520)
  Proceeds from sale of property, plant and equipment ..................               40,052                   2,792
                                                                                    ---------               ---------

          Net cash used in investing activities ........................             (167,050)                (13,728)
                                                                                    ---------               ---------

Cash flows from financing activities:
  Proceeds from long-term borrowings ...................................              172,639                   2,673
  Principal payments on debt ...........................................               (2,090)                (31,641)
  Proceeds from issuance of common stock ...............................                3,011                   5,112
  Purchase of treasury stock, at cost ..................................              (86,021)                      -
  (Increase) decrease in funds held by trustee .........................               (1,034)                    133
                                                                                    ---------               ---------

          Net cash provided by (used in) financing activities ..........               86,505                 (23,723)
                                                                                    ---------               ---------

                Net increase in cash and cash equivalents ..............               47,897                  17,580

Cash and cash equivalents at beginning of period .......................               70,263                  16,471
                                                                                    ---------               ---------

Cash and cash equivalents at end of period .............................            $ 118,160               $  34,051
                                                                                    =========               =========


                             See accompanying notes.

                                        5



                       HEALTH MANAGEMENT ASSOCIATES, INC.
          NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

1.  Basis of Presentation

         The condensed consolidated balance sheet as of September 30, 2001 has
been derived from the audited consolidated financial statements included in
Health Management Associates, Inc.'s (the "Company's") 2001 Annual Report on
Form 10-K. The interim condensed consolidated financial statements at December
31, 2001 and for the three months ended December 31, 2001 and 2000 are
unaudited; however, such interim statements reflect all adjustments (consisting
only of a normal recurring nature) which are, in the opinion of management,
necessary for a fair presentation of the financial position and results of
operations for the interim periods presented. The results of operations for the
interim periods presented are not necessarily indicative of the results to be
expected for the full year. The interim financial statements should be read in
conjunction with the audited consolidated financial statements of the Company
included in its 2001 Annual Report on Form 10-K.

2.  Use of Estimates

         The preparation of financial statements in conformity with generally
accepted accounting principles requires management of the Company to make
estimates and assumptions that affect the amounts reported in the condensed
consolidated financial statements. Actual results could differ from the
estimates.

3.  Earnings Per Share

         The following table sets forth the computation of basic and diluted
earnings per share (in thousands, except per share data):

                                            Three months ended
                                               December 31,
                                          ---------------------
                                            2001         2000
                                          --------     --------
Numerator:
   Numerator for basic earnings per
    share-net income                      $ 50,466     $ 40,178
   Effect of convertible debt                1,355        1,337
                                          --------     --------
   Numerator for diluted earnings
    per share                             $ 51,821     $ 41,515
                                          ========     ========

Denominator:
   Denominator for basic earnings
    per share-weighted average shares      243,649      243,234
   Effect of dilutive securities:
    Employee stock options                   5,267        6,614
    Convertible debt                        14,449       14,449
                                          --------     --------
   Denominator for diluted earnings
    per share                              263,365      264,297
                                          ========     ========

Basic earnings per share                  $    .21     $    .17
                                          ========     ========
Diluted earnings per share                $    .20     $    .16
                                          ========     ========

                                        6



                       HEALTH MANAGEMENT ASSOCIATES, INC.
          NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

4.  Acquisitions

         Effective December 1, 2001, the Company acquired the East Pointe
Hospital pursuant to an Asset Purchase Agreement. The Agreement included the
purchase of substantially all property, plant and equipment of the hospital. The
total consideration approximated $16.5 million in cash. The Company used cash on
hand to finance the cost of this transaction.

         Effective January 1, 2002, the Company completed the acquisition of
four acute-care hospitals from Clarent Hospital Corporation for approximately
$170 million in cash. On the same day the Company sold one of these hospitals to
Universal Health Services, Inc. for $40.0 million in cash. The Company used
amounts available under its credit agreement to finance the net cost of these
transactions. These transactions closed on December 31, 2001 with an effective
date of January 1, 2002 and are reflected in the Company's balance sheet and
statement of cash flows as of December 31, 2001 and for the three month period
then ended.

5. Recent Accounting Pronouncements

         As of July 1, 2001, the Company adopted the provisions of SFAS No. 141,
Business Combinations, and as of October 1, 2001, the Company adopted the
provisions of SFAS No. 142, Goodwill and Other Intangible Assets. SFAS No. 141
requires that the purchase method of accounting be used for all business
combinations entered into after June 30, 2001. SFAS No. 141 also specifies
criteria intangible assets acquired in a purchase method business combination
must meet to be recognized and reported apart from goodwill, noting that any
purchase price allocable to an assembled workforce may not be accounted for
separately. SFAS No. 142 requires that goodwill and intangible assets with
indefinite useful lives no longer be amortized, but instead tested for
impairment at least annually in accordance with the provisions of SFAS No. 142.
The transition provisions of SFAS No. 142 require the completion of a
transitional impairment test within six months of adoption of SFAS No. 142, with
any impairments identified accounted for as a cumulative effect of a change in
accounting principal.

         In accordance with SFAS No. 142, the Company discontinued the
amortization of goodwill effective October 1, 2001. During the quarter ended
December 31, 2000, the Company recorded approximately $2.2 million of goodwill
amortization expense which reduced earnings by approximately $1.3 million (net
of tax expense of approximately $0.9 million), or approximately $0.005 per
share, basic and diluted.

         The Company has not yet determined the effect of adoption of the
impairment testing requirements of SFAS No. 142 on the Company's business,
results of operations, or financial condition. The Company will perform and
report the results of its transitional impairment tests under SFAS No. 142 in
the Company's March 31, 2002 financial statements.

                                        7



                       HEALTH MANAGEMENT ASSOCIATES, INC.
          NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

6.  Subsequent Events

     On January 28, 2002, the Company issued and sold $330.0 million in face
value of Zero-Coupon Convertible Senior Subordinated Notes (the "Notes") for
gross proceeds of approximately $277.0 million. The Notes are the Company's
general unsecured obligations and are subordinated in right of payment to the
Company's existing and future indebtedness that is not, by its terms, expressly
subordinated or pari passu in right of payments to the Notes. The Company's
Convertible Senior Subordinated Debentures due 2020 (the "Debentures") rank pari
passu with the Notes. The Notes mature on January 28, 2022 unless converted or
redeemed earlier. Upon the occurrence of certain events, the Notes are
convertible into the Company's common stock at a conversion rate of 32.1644
shares of common stock for each $1,000 principal amount of the Notes (equivalent
to a conversion price of $26.11 per share). The equivalent number of shares
associated with the offering become dilutive (included in the Company's earnings
per share calculation) when the Company's common stock attains a level of $31.33
for at least 20 trading days of the 30 trading days prior to the conversion or
the Notes otherwise become convertible. The accrual of original issue discount
represents a yield to maturity of 0.875% per year calculated from January 22,
2002, excluding any contingent interest.

     Holders may require the Company to purchase all or a portion of their Notes
on January 28, 2005, January 28, 2007, January 28, 2012 and January 28, 2017 for
a purchase price per note of $862.07, $877.25, $916.40 and $957.29,
respectively, plus accrued and unpaid interest to each purchase date. The
Company will pay cash for all Notes so purchased on January 28, 2005. The
Company may choose to pay the purchase price in cash or common stock or a
combination of cash and common stock for purchases on or after January 28, 2007.
In addition, upon a change in control of the Company occurring on or before
January 28, 2007, each holder may require the Company to purchase all or a
portion of such holder's Notes. The Company may redeem all or a portion of the
Notes at any time on or after January 28, 2007. The Company has agreed to file
a registration statement with respect to the Notes and shares of common stock
underlying the Notes by April 29, 2002 and to have such registration statement
become effective by June 27, 2002.

      On January 29, 2002, the Company announced that it had completed its
current stock repurchase program. The Company purchased a total of 5,000,000
shares of the Company's common stock since September 2001 under the program.

                                        8



Item 2.  Management's discussion and Analysis of Financial
         Condition and Results of Operations

         Results of Operations

         Three months ended December 31, 2001 compared
         to three months ended December 31, 2000

                 Net patient service revenue for the three months ended December
         31, 2001 ("2002 Period") was $495.8 million, as compared to $434.2
         million for the three months ended December 31, 2000 ("2001 Period").
         This represented an increase in net patient service revenue of $61.6
         million, or 14.2%. Hospitals in operation for the entire 2002 Period
         and 2001 Period ("same hospitals") provided $36.6 million of the
         increase in net patient service revenue which resulted primarily from
         inpatient and outpatient volume increases and rate increases. The
         remaining net increase of $25.0 million included $24.9 million of net
         patient service revenue from the June 2001 acquisition of a 200-bed
         hospital, the September 2001 acquisition of an 80-bed hospital and the
         December 2001 acquisition of an 88-bed hospital, and an increase of
         $0.1 million in miscellaneous other revenue.

                 During the 2002 Period the Company's hospitals generated
         patient days of service and an occupancy rate of 223,702 and 45.5%,
         respectively, versus 209,431 and 44.7%, respectively, for the 2001
         Period. Same hospital patient days and occupancy rates were 201,323 and
         44.6%, respectively, for the 2002 Period, and 196,393 and 43.5%,
         respectively, for the 2001 Period. Same hospital admissions for the
         Company during the 2002 Period were 45,302, up 1.8% from the 44,486
         admissions during the 2001 Period.

                 The Company's operating expenses (salaries and benefits,
         supplies and other, provision for doubtful accounts and rent expense)
         for the 2002 Period were $387.0 million, or 78.1% of net patient
         service revenue as compared to $340.6 million or 78.4% of net patient
         service revenue for the 2001 Period. Of the total $46.4 million
         increase, approximately $22.1 million related to same hospitals, which
         was largely attributable to increased patient volumes. Another $22.6
         million of increased operating expenses related to the hospital
         acquisitions mentioned previously. The remaining increase of $1.7
         million represented the net increase in Corporate and other operating
         expenses offset by a decrease of $0.5 million of expenses resulting
         from the closure of one psychiatric facility in December 2000.


                 The Company's depreciation and amortization costs increased by
         $0.2 million and interest expense decreased by $2.0 million. The
         increase in depreciation and amortization resulted primarily from the
         acquisitions previously mentioned which were offset by a decrease in
         amortization expense of $2.2 million related to the Company's adoption
         of SFAS No. 142. The decrease in interest expense was due to lower
         interest rates on the Company's Credit Agreement (as defined herein)
         and lower average balances outstanding on the Credit Agreement in the
         2002 Period.

                 The Company's income before income taxes was $83.1 million for
         the 2002 Period as compared to $66.1 million for the 2001 Period, an
         increase of $17.0 million or 25.7%. The increase resulted primarily
         from same hospital volume increases and the acquisitions mentioned
         previously.

                                        9



Item 2.  Management's Discussion and Analysis of Financial
         Condition and Results of Operations (Continued)

         Results of Operations

         Three months ended December 31, 2001 compared
         to three months ended December 31, 2000 (continued)

                 The Company's provision for income taxes was $32.6 million for
         the 2002 Period, as compared to $25.9 million for the 2001 Period.
         These provisions reflect effective income tax rates of approximately
         39.2% for both periods. As a result of the foregoing, the Company's net
         income was $50.5 million for the 2002 Period as compared to $40.2
         million for the 2001 Period.

         Liquidity and Capital Resources

         2002 Three Month Period Cash Flows compared to 2001 Three Month Period
         Cash Flows

                 The Company's operating cash flows totaled $128.4 million
         for the 2002 Period as compared to $55.0 million for the 2001 Period.
         The continued positive cash flows from operating activities result from
         the Company's profitability and management of its working capital. The
         Company's investing activities used $167.1 million and $13.7 million
         for the 2002 Period and 2001 Period, respectively. Acquisition of
         hospitals accounted for the majority of the expenditures in the 2002
         Period. Ongoing renovation and capital equipment costs accounted for
         the majority of the expenditures in the 2001 Period. Financing
         activities provided for $86.5 million for the 2002 Period and used
         $23.7 for the 2001 period. Increased borrowings to finance
         acquisitions, offset by purchases of treasury stock, accounted for the
         majority of the increase in the 2002 period. See the Condensed
         Consolidated Statements of Cash Flows for the three months ended
         December 31, 2001 and 2000 at page 5 of this Report.

         Capital Resources

                 The Company currently has a 5-year $450 million Credit
         Agreement (the "Credit Agreement") due November 30, 2004. The Credit
         Agreement is a term loan agreement which permits the Company to borrow
         under an unsecured revolving credit loan at any time through November
         30, 2004, at which time the agreement terminates and all outstanding
         amounts become due and payable. The Company may choose a Base Rate Loan
         (prime interest rate) or a Eurodollar Rate Loan (LIBOR interest rate).
         The interest rate for a Eurodollar Rate Loan is currently LIBOR plus
         1.00 percent, and will increase or decrease in relation to a change in
         the Company's credit rating. Monthly or quarterly interest payments are
         required depending on the type of loan chosen by the Company. The
         interest rate on the outstanding balance at December 31, 2001 and
         December 31, 2000 was 2.9% and 7.6%, respectively.

                 The Company also has a $15 million unsecured revolving credit
         commitment with a bank. The $15 million credit is a working capital
         commitment which is tied to the Company's cash management system, and
         renews annually in December. Currently, interest on any outstanding
         balance is

                                       10



Item 2.    Management's Discussion and Analysis of Financial Condition and
           Results of Operations (Continued)

           payable monthly at a fluctuating rate not to exceed the bank's prime
           rate less .25%. The interest rate at December 30, 2001 and 2000 was
           4.75% and 9.5% respectively. As of December 31, 2001, there were no
           amounts outstanding under this credit commitment.

                      In addition, the Company is obligated to pay certain
           commitment fees based upon amounts available for borrowing during the
           terms of the credit agreements described above.

                      The credit agreements contain covenants which, without
           prior consent of the banks, limit certain activities, including those
           relating to mergers, consolidations and the Company's ability to
           secure additional indebtedness, make guarantees, grant security
           interests and declare dividends. The Company must also maintain
           minimum levels of consolidated tangible net worth, debt service
           coverage and interest coverage. At December 31, 2001, the Company was
           in compliance with these covenants.

                      On August 16, 2000, the Company sold $488.8 million face
           value of Convertible Senior Subordinated Debentures due 2020 for
           gross proceeds of $287.7 million. The Debentures mature on August 16,
           2020 unless converted or redeemed earlier. The Debentures are
           convertible into the Company's common stock at a conversion rate of
           29.5623 shares of common stock for each $1,000 principal amount of
           the Debentures (equivalent to a conversion price of $19.9125 per
           share). Interest on the Debentures is payable semiannually in arrears
           on August 16 and February 16 of each year at a rate of .25% per year
           on the principal amount at maturity. The rate of cash interest and
           accrual of original issue discount represent a yield to maturity of
           3% per year calculated from August 16, 2000.

                      Holders may require the Company to purchase all or a
           portion of their Debentures on August 16, 2003, August 16, 2008 and
           August 16, 2013 for a purchase price per Debenture of $635.88,
           $724.85 and $827.53, respectively, plus accrued and unpaid interest
           to each purchase date. The Company may choose to pay the purchase
           price in cash or common stock or a combination of cash and common
           stock. In addition, upon a change in control of the Company occurring
           on or before August 16, 2003, each holder may require the Company to
           repurchase all or a portion of such holder's Debentures. The Company
           may redeem all or a portion of the Debentures at any time on or after
           August 16, 2003.

                      On January 28, 2002, the Company issued and sold
          $330.0 million face value of Zero-Coupon Convertible Senior
          Subordinated Notes due 2022 for gross proceeds of approximately $277.0
          million. See footnote 6 to the Interim Condensed Consolidated
          Financial Statements.

           Forward-Looking Statements
           --------------------------

                      Certain statements contained in this Form 10-Q, including,
           without limitation, statements containing the words "believes,"
           "anticipates," "intends," " expects" and words of similar import,
           constitute "forward-looking statements" within the meaning of the
           Private Securities Litigation Reform Act of 1995. Such
           forward-looking statements involve known and unknown risks,
           uncertainties and other factors that may cause the actual results,
           performance or achievements of the Company or industry results to be
           materially different from any future results, performance or
           achievements
Item 2.    Management's Discussion and Analysis of Financial Condition and
           Results of Operations (Continued)

                                       11



           Forward-Looking Statements (continued)
           --------------------------

           expressed or implied by such forward-looking statements. Such factors
           include, among others, the following: general economic and business
           conditions, both nationally and in the regions in which the Company
           operates; industry capacity; demographic changes; existing
           governmental regulations and changes in, or the failure to comply
           with, governmental regulations; legislative proposals for health care
           reform; the ability to enter into managed care proposals for health
           care reform; the ability to enter into Medicare and Medicaid payment
           levels; liability and other claims asserted against the Company;
           competition; the loss of any significant ability to attract and
           retain qualified personnel, including physicians; the availability
           and terms of capital to fund additional acquisitions or replacement
           facilities. Given these uncertainties, prospective investors are
           cautioned not to place undue reliance on such forward-looking
           statements. The Company disclaims any obligation to update any such
           factors or to publicly announce the results of any revision to any of
           the forward-looking statements contained herein to reflect future
           events or developments.

Item 3.    Quantitative and Qualitative Disclosures about Market Risk
     -     ----------------------------------------------------------

           During the three months ended December 31, 2001, there were no
           material changes in the quantitative and qualitative disclosures
           about market risks presented in Item 7A in the Company's Annual
           Report on Form 10-K for the year ended September 30, 2001, other
           than the change as described below.

           During the three months ended December 31, 2001, the Company
           increased its borrowings under its variable rate revolving line of
           credit agreement by $170 million.


                                       12



                           PART II - OTHER INFORMATION


Item 1.    Legal Proceedings.
           -----------------

           None.


Item 2.    Changes in Securities.
           ---------------------

           None.


Item 3.    Defaults upon Senior Securities.
           -------------------------------

           None.


Item 4.    Submission of Matters to a Vote of Security Holders.
           ---------------------------------------------------

           None.

Item 5.    Other Information
           -----------------

           None

Item 6.    Exhibits and Reports on Form 8-K.
           --------------------------------

           a.  Exhibits:
               --------

               See Index to Exhibits located on page 15

           b.  Reports on Form 8-K:
               -------------------

               Form  8-K Reporting Date--January 24, 2002
                         Item Reported--Item 5. Other Events and Regulation
                         FD Disclosure. The Company reported the offering of
                         approximately $277 million (gross proceeds) of
                         Zero-Coupon Convertible Senior Subordinated Notes
                         due 2022 to qualified institutional buyers.

               Form 8-K Reporting Date--Fabruary 13, 2002
                         Item Reported--Item 5. Other Events and Regulation
                         FD Disclosure. The Company reported the closing of
                         the offering of approximately $277 million (gross
                         proceeds) of Zero-Coupon Convertible Senior
                         Subordinated Notes due 2022 to qualified
                         institutional buyers.


                                       13



                                   SIGNATURES


           Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this Report to be signed on its behalf by the
undersigned, thereunto duly authorized.



                                         HEALTH MANAGEMENT ASSOCIATES, INC.




DATE:  February 13, 2002                  BY:   /s/ Robert E. Farnham
                                              ----------------------
                                              Robert E. Farnham
                                              Senior Vice President and
                                              Chief Financial Officer
                                              (Principal Financial Officer
                                              and Principal Accounting Officer)

                                       14



                                INDEX TO EXHIBITS


(2)        Plan of acquisition, reorganization, arrangement, liquidation or
     succession.

     Not applicable.

(3)  (i)  Articles of Incorporation

     3.1   The Fifth Restated Certificate of Incorporation, previously filed and
           included as Exhibit 3.1 to the Company's Quarterly Report on Form
           10-Q for the quarter ended March 31, 1995, is incorporated herein by
           reference.

     3.2   Certificate of Amendment to Fifth Restated Certificate of
           Incorporation, previously filed and included as Exhibit 3.2 to the
           Company's Annual Report on Form 10-K for the year ended September 30,
           1999, is incorporated herein by reference.

     (ii)  By-laws

     3.3   The By-laws, as amended, previously filed and included as Exhibit 3.3
           to the Company's Quarterly Report on Form 10-Q for the quarter ended
           March 31, 2000, is incorporated herein by reference.

(4)  Instruments defining the rights of security holders, including indentures.

     The Exhibits referenced under (3) of this Index to Exhibits are
     incorporated herein by reference.

     4.1   Specimen Stock Certificate, previously filed and included as Exhibit
           4.11 to the Company's Annual Report on Form 10-K for the fiscal year
           ended September 30, 1992, is incorporated herein by reference.

     4.5   Credit Agreement by and among Health Management Associates, Inc., as
           Borrower, Bank of America, N.A., as Administrative Agent and as
           Lender, First Union National Bank, as Syndication Agent and as
           Lender, and the Chase Manhattan Bank, as Syndication Agent and as
           Lender, and The Lenders Party Hereto From Time To Time, dated
           November 30, 1999, previously filed and included as Exhibit 4.5 to
           the Company's Annual Report on Form 10-K for the fiscal year ended
           September 30, 1999, is incorporated herein by reference.

     4.6   Credit Agreement dated March 23, 2000 between First Union National
           Bank and Health Management Associates, Inc., pertaining to a $15
           million working capital and cash management line of credit,
           previously filed and included as Exhibit 4.1 to the Company's
           Quarterly Report on Form 10-Q for the quarter ended March 30, 2000,
           is incorporated herein by reference.

     4.7   Indenture dated August 16, 2000 between Health Management Associates,
           Inc. and First Union National Bank, pertaining to the $488.7 million
           face value of Convertible Senior Subordinated Debentures due 2020,
           previously filed and included as Exhibit 4.1(1) to the Company's Form
           S-3 Registration Statement filed October 27, 2000, is incorporated
           herein by reference.

(10) Material contracts.

     10.1  Amendment No. 8 to the Health Management Associates, Inc. Stock
           Option Plan for Outside Directors.

                                       15



                          INDEX TO EXHIBITS (Continued)



(11)     Statement re computation of per share earnings.

         Not applicable.

(15)     Letter re unaudited interim financial information.

         Not applicable.

(18)     Letter re change in accounting principles.

         Not applicable.

(19)     Report furnished to security holders.

         Not applicable.

(22)     Published report regarding matters submitted to vote of security
         holders.

         Not applicable.

(23)     Consents of experts and counsel.

         Not applicable.

(24)     Power of attorney.

         Not applicable.

(99)     Additional exhibits.

         Not applicable.

                                       16